K J Doyle1, C E McLaren, J E Shanks, C M Galus, F L Meyskens. 1. Department of Otolaryngology-Head and Neck Surgery, University of California Davis Medical Center, Sacramento, CA 95817, USA. karen.doyle@ucdmc.ucdavis.edu
Abstract
OBJECTIVES: To determine the effects of long-term, low-dose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. DESIGN: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. SETTING:Academic tertiary care referral center. PARTICIPANTS: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. INTERVENTIONS: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) of body surface area for 12 months. OUTCOME MEASURES: Pure-tone audiometric thresholds for the frequencies 250, 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. RESULTS: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. CONCLUSIONS: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.
RCT Entities:
OBJECTIVES: To determine the effects of long-term, low-dose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. DESIGN: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. SETTING: Academic tertiary care referral center. PARTICIPANTS: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. INTERVENTIONS: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) of body surface area for 12 months. OUTCOME MEASURES: Pure-tone audiometric thresholds for the frequencies 250, 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. RESULTS: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. CONCLUSIONS: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.
Authors: Ning Qu; Natalia A Ignatenko; Phillip Yamauchi; David E Stringer; Corey Levenson; Patrick Shannon; Scott Perrin; Eugene W Gerner Journal: Biochem J Date: 2003-10-15 Impact factor: 3.857
Authors: Christine E McLaren; Sharon Fujikawa-Brooks; Wen-Pin Chen; Daniel L Gillen; Daniel Pelot; Eugene W Gerner; Frank L Meyskens Journal: Cancer Prev Res (Phila) Date: 2008-12
Authors: Anne R Simoneau; Eugene W Gerner; Ray Nagle; Argyrios Ziogas; Sharon Fujikawa-Brooks; Hagit Yerushalmi; Thomas E Ahlering; Ronald Lieberman; Christine E McLaren; Hoda Anton-Culver; Frank L Meyskens Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-02 Impact factor: 4.254
Authors: Xiaojing Wang; Snezana Levic; Michael Anne Gratton; Karen Jo Doyle; Ebenezer N Yamoah; Anthony E Pegg Journal: J Biol Chem Date: 2008-11-10 Impact factor: 5.157